Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

H Stone, John; A Merkel, Peter; Spiera, Robert; Seo, Philip; A Langford, Carol; S Hoffman, Gary; G M Kallenberg, Cees; William St Clair, E; Turkiewicz, Anthony; K Tchao, Nadia; Webber, Lisa; Ding, Linna; P Sejismundo, Lourdes; Mieras, Kathleen; Weitzenkamp, David; Ikle, David; Seyfert-Margolis, Vicki; Mueller, Mark; Brunetta, Paul; B Allen, Nancy; C Fervenza, Fernando; Geetha, Duvuru; A Keogh, Karina; Y Kissin, Eugene; A Monach, Paul; Peikert, Tobias; Stegeman, Coen; R Ytterberg, Steven; Specks, Ulrich; Research Group, RAVE-ITN

doi:10.1056/NEJMoa0909905

Public

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Shared by NobleBlocks on Jul 15, 2010 • 12:00 AM UTC

Authors:

John H Stone

Peter A Merkel

Robert Spiera

Abstract

BACKGROUND: Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based ...

Discussions